Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for ...
Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with exte...
- Cipla USA Inc. the wholly owned subsidiary of Cipla Limited announced final approval from the U.S. Food and Drug Administration (USFDA) for its Abbrevi...
Government investment will accelerate clinical development and strengthen Aspect’s advanced biomanufacturing capabilities for its bioengineered c...
H2 Global Group is strengthening its position as a European technology group connecting capital with clinically validated healthcare innovations. A prime...
Global pharma major Lupin Limited (Lupin) announced the completion of its acquisition of VISUfarma B.V. (VISUfarma), a leading European specialty pha...
Tanner Pharma Group, a global provider of specialty medicine access solutions, and Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmace...
Meiji Seika Pharma Co., Ltd. announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company deve...
Emergent BioSolutions Inc. announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Glo...
Continuity Biosciences and Breakthrough T1D, the leading global type 1 diabetes (T1D) advocacy organization, today announced a strategic collaboration to...
MARS Bioimaging Extremity Scanner System is designed for premium musculoskeletal imaging in the community Advanced photon-counting CT technology delive...
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER...
HUTCHMED (China) announces that it has initiated a registrational Phase III clinical trial of HMPL-760 in combination with R-GemOx (rituximab, gemcitabin...
In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination ...
© 2026 Biopharma Boardroom. All Rights Reserved.
